Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 00:57 ET | Source: Vifor Pharma Ltd.

Galenica commences Tender Offer for Relypsa

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Galenica Group today announced that...
July 21, 2016 01:01 ET | Source: Vifor Pharma Ltd.

Galenica to acquire Relypsa to strengthen its Business unit Vifor Pharma

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Galenica and Relypsa announce...
May 24, 2016 00:59 ET | Source: Vifor Pharma Ltd.

Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer's proposed epoetin alfa biosimilar, Retacrit(TM), in the US dialysis market

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Vifor Pharma, a company of the...
May 23, 2016 01:31 ET | Source: Vifor Pharma Ltd.

The 2016 ESC heart failure guidelines strongly recommend Ferinject® for the treatment of iron deficiency in patients with systolic heart failure

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Iron deficiency is confirmed as...
May 10, 2016 01:31 ET | Source: Vifor Pharma Ltd.

Vifor Pharma appoints Colin Bond as Chief Financial Officer

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Vifor Pharma today announced the...
May 10, 2016 01:02 ET | Source: Vifor Pharma Ltd.

Vifor Pharma Licenses Rights to Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Vifor Pharma to market drug in...
May 09, 2016 01:30 ET | Source: Vifor Pharma Ltd.

Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter Into Agreement for OPKO's RAYALDEE(R)

Vifor Fresenius Medical Care Renal Pharma obtains rights to commercialize RAYALDEE® in Europe, Canada and certain other international markets OPKO to receive up to USD 282 million in...
May 09, 2016 01:05 ET | Source: Vifor Pharma Ltd.

Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO's RAYALDEE®

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Vifor Fresenius Medical Care Renal...
April 25, 2016 01:11 ET | Source: Vifor Pharma Ltd.

Vifor Fresenius Medical Care Renal Pharma and Relypsa announce Submission of Marketing Authorisation Application Requesting European Approval of Patiromer for treatment of hyperkalemia

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Vifor Fresenius Medical Care Renal...
December 15, 2015 01:20 ET | Source: Vifor Pharma Ltd.

Swissmedic autorise l'utilisation en Suisse d'Akynzeo® (nétupitant/palonosétron) pour la prévention des nausées et vomissements induits par la chimiothérapie (CINV)

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Première combinaison fixe ciblant deux des...